q-1802
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2021 (NCT04856150)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death 1 ligand 1ANTAGONIST
PDL1
- Claudin-18ANTAGONIST
CLDN18 antagonist
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05964543 | Phase 1/Phase 2 (Phase 2) | Jun 21, 2023 | Qure Healthcare, LLC |
| NCT04856150 | Phase 1 | May 31, 2021 | Qure Healthcare, LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qure Healthcare, LLC | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1